TABLE 2

Characterization of the binding specificities of three important prototype anti-METH/MDMA or anti-METH/MDMA/AMP mAb

Drug
Antibody Specificity (Relative Potency to METH)a
11 nM mAb6H4b
 250 nM mAb6H8b
 34 nM mAb4G9b
(+)-METH 1.00 1.00 1.00
(+)-AMP 0.001 0.023 0.34
(+)-MDMA 1.25 3.40 0.29
(-)-METH 0.030 0.011 0.102
(-)-AMP <0.001 0.003 0.063
(-)-MDMA 0.007 0.018 0.011
(+)-3,4-Methylenedioxyamphetamine 0.001 0.024 0.090
(-)-3,4-Methylenedioxyamphetamine <0.001 <0.001 0.002
4-OH-METH 0.588 0.294 0.106
(+)-Pseudoephedrine <0.001 0.018 0.004
(+)-Norpseudoephedrine <0.001 <0.001 <0.001
l-Phenylphrine 0.001 <0.001 <0.001
(+)-Ephedrine <0.001 <0.001 <0.001
(+)-Phenylpropanolamine <0.001 <0.001 <0.001
β-Phenylethylamine <0.001 <0.001 <0.001
Tyramine <0.001 <0.001 <0.001
Dopamine <0.001 <0.001 <0.001
Norepinepherine <0.001 <0.001 <0.001
Serotonin <0.001 <0.001 <0.001
Epinephrine
<0.001
<0.001
<0.001

  • ↵ a Relative potency to METH = (RlA IC50 value for METH/RlA IC50 value for test ligand). See Table 1 for the structures of the haptens used to generate these antibodies.

  • ↵ b IC50 value for METH binding from Table 1.